{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:27:18Z","timestamp":1773815238885,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12288-019-01152-3","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T16:02:41Z","timestamp":1561132961000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India"],"prefix":"10.1007","volume":"35","author":[{"given":"Ajay","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chezian","family":"Subhash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharma","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Easow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Sidharthan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-8491","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revathy","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya Prakash","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharat","family":"Damodar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soniya","family":"Nityanand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulika","family":"Seth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velu","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"1152_CR1","unstructured":"https:\/\/www.bbmt.org\/issue\/S1083-8791(18)X0014-7"},{"key":"1152_CR2","unstructured":"https:\/\/www.indusbmt.org\/\n                    \n                  . Accessed 3 May 2019"},{"key":"1152_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","volume":"53","author":"M Horowitz","year":"2018","unstructured":"Horowitz M, Schreiber H, Elder A et al (2018) Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant 53:1379\u20131389","journal-title":"Bone Marrow Transplant"},{"key":"1152_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.bbmt.2018.12.685","volume":"25","author":"D Beelen","year":"2019","unstructured":"Beelen D et al (2019) Final evaluation of a clinical phase III trial comparing treosulfan to busulfan-based conditioning therapy prior to allogeneic hematopoietic stem cell transplantation of adult acute myeloid leukemia and myelodysplastic syndrome patients ineligible to standard myeloablative regimens. Biol Blood Marrow Transplant 25:S3","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR5","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1016\/S2352-3026(18)30156-X","volume":"5","author":"UR Popat","year":"2018","unstructured":"Popat UR, Mehta RS, Bassett R et al (2018) Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5:e532\u2013e542","journal-title":"Lancet Haematol"},{"key":"1152_CR6","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/j.bbmt.2018.12.775","volume":"25","author":"SL Hyzy","year":"2019","unstructured":"Hyzy SL et al (2019) CD45-targeted antibody drug conjugate plus post transplant cytoxan is sufficient to enable allogeneic bone marrow transplant in a minor mismatch mouse model. Biol Blood Marrow Transplant 25:S188\u2013S189","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"1152_CR7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2018-99-111582","volume":"132","author":"B Oran","year":"2018","unstructured":"Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Alousi AM, Hosing C, Kebriaei P, Popat U, Giralt S, Ahmed S, Shpall EJ, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Woodworth G, Champlin RE (2018) Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients. Blood 132(Suppl 1):971","journal-title":"Blood"},{"key":"1152_CR8","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.bbmt.2018.12.077","volume":"25","author":"RT Maziarz","year":"2019","unstructured":"Maziarz RT et al (2019) Radius: midostaurin [mido] plus standard of care [SOC] after allogeneic stem cell transplant [alloSCT] in patients [pts] with FLT3-internal tandem duplication [ITD]-mutated acute myeloid leukemia [AML]. Biol Blood Marrow Transplant 25:S11\u2013S12","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR9","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.bbmt.2018.12.092","volume":"25","author":"S Bal","year":"2019","unstructured":"Bal S et al (2019) Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma. Biol Blood Marrow Transplant 25:S22\u2013S23","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR10","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.bbmt.2018.12.090","volume":"25","author":"SA Srour","year":"2019","unstructured":"Srour SA et al (2019) Melphalan dose intensity for autologous stem cell transplantation [ASCT] in multiple myeloma. Biol Blood Marrow Transplant 25:S21","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR11","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.bbmt.2018.12.087","volume":"25","author":"G Morgan","year":"2019","unstructured":"Morgan G et al (2019) Maintenance therapy with the oral proteasome inhibitor [PI] ixazomib significantly prolongs progression-free survival [PFS] following autologous stem cell transplantation [ASCT] in patients with newly diagnosed multiple myeloma [NDMM]: phase 3 tourmaline-MM3 trial. Biol Blood Marrow Transplant 25:S19\u2013S20","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR12","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1016\/j.bbmt.2018.12.651","volume":"25","author":"ZD Crees","year":"2019","unstructured":"Crees ZD et al (2019) Genesis\u2014a phase III randomized double-blind, placebo-controlled, multi-center trial evaluating the safety and efficacy of BL-8040 and G-CSF in mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma\u2014lead-in period results. Biol Blood Marrow Transplant 25:S308\u2013S309","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR13","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1016\/j.bbmt.2018.12.785","volume":"25","author":"AA Pai","year":"2019","unstructured":"Pai AA et al (2019) Pharmacokinetics and efficacy of generic melphalan is comparable to innovator formulation in patients with multiple myeloma undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 25:S196","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR14","doi-asserted-by":"publisher","first-page":"S395","DOI":"10.1016\/j.bbmt.2018.12.808","volume":"25","author":"A Gandhi","year":"2019","unstructured":"Gandhi A et al (2019) Dose-intense BCNU\/melphalan regimen followed by autologous hematopoietic cell transplantation [AHCT] results in prolonged PFS in myeloma patients. Biol Blood Marrow Transplant 25:S395\u2013S396","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/cancers11030421","volume":"11","author":"AA Mina","year":"2019","unstructured":"Mina AA, Vakkalagadda C, Pro B (2019) Novel therapies and approaches to relapsed\/refractory HL beyond chemotherapy. Cancers 11:421","journal-title":"Cancers"},{"key":"1152_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","volume":"132","author":"C Herbaux","year":"2018","unstructured":"Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B (2018) Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 132:9\u201316","journal-title":"Blood"},{"key":"1152_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41564-019-0373-1","volume":"4","author":"T Toubai","year":"2019","unstructured":"Toubai T, Fujiwara H, Rossi C et al (2019) Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nat Microbiol 4:800\u2013812","journal-title":"Nat Microbiol"},{"key":"1152_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.medcli.2018.07.012","volume":"152","author":"DF Moreno","year":"2019","unstructured":"Moreno DF, Cid J (2019) Graft-versus-host disease. Med Clin (Barc) 152:22\u201328","journal-title":"Med Clin (Barc)"},{"key":"1152_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","volume":"133","author":"S Sarantopoulos","year":"2019","unstructured":"Sarantopoulos S, Cardones AR, Sullivan KM (2019) How we treat refractory chronic graft-versus-host disease. Blood 133:1191\u20131200","journal-title":"Blood"},{"key":"1152_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41409-018-0333-z","volume":"54","author":"MS Saleem","year":"2019","unstructured":"Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, El Haddad A, Hashmi SK (2019) Challenges in managing graft-versus-host disease in developing countries: a perspective. Bone Marrow Transplant 54:641\u2013647","journal-title":"Bone Marrow Transplant"},{"key":"1152_CR21","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbmt.2018.06.025","volume":"24","author":"KM Sullivan","year":"2019","unstructured":"Sullivan KM et al (2019) Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the american society for blood and marrow transplantation. Biol Blood Marrow Transplant 24:1961\u20131964","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"1152_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L et al (2018) SCOT study investigators. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(4):35\u201347.","journal-title":"N Engl J Med"},{"key":"1152_CR23","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1016\/j.bbmt.2018.12.638","volume":"25","author":"J de la Fuente","year":"2019","unstructured":"de la Fuente J et al (2019) Augmenting non-myeloablative BMT with Ptcy using thiotepa or 400 Cgy TBI improves engraftment in patients with transfusion dependent thalassemia: results of a haploidentical transplant consortium for hemoglobinopathies [ICHH]. Biol Blood Marrow Transplant 25:S310\u2013S311","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR24","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1016\/j.bbmt.2018.12.637","volume":"25","author":"BG Long","year":"2019","unstructured":"Long BG et al (2019) Assessment of safety and efficacy of PBSC mobilization with G-CSF and CD34+ enrichment and Pbmnc [CD3+] addback in familial haploidentical [FHI] adult donors with sickle cell disease trait [SCDT] prior to allogeneic HSCT of high-risk SCD patients. Biol Blood Marrow Transplant 25:S310","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR25","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.bbmt.2018.12.150","volume":"25","author":"U Anurathapan","year":"2019","unstructured":"Anurathapan U et al (2019) Lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia: outcomes from the phase 1\/2 Northstar and phase 3 Northstar-2 studies. Biol Blood Marrow Transplant 25:S66\u2013S67","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR26","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.bbmt.2018.12.147","volume":"25","author":"MY Mapara","year":"2019","unstructured":"Mapara MY et al (2019) Lentiglobin gene therapy in patients with sickle cell disease: updated interim results from Hgb-206. Biol Blood Marrow Transplant 25:S64\u2013S65","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR27","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.bbmt.2018.12.080","volume":"25","author":"F Galaverna","year":"2019","unstructured":"Galaverna F et al (2019) Administration of BPX-501 cells following \u0391\u03b2 T and B-cell-depleted HLA-haploidentical HSCT [haplo-HSCT] in children with malignant or non-malignant disorders. Biol Blood Marrow Transplant 25:S13\u2013S14","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR28","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.bbmt.2018.12.172","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R et al (2019) Toxicity-free hematopoietic stem cell engraftment achieved with anti-CD117 monoclonal antibody conditioning. Biol Blood Marrow Transplant 25:S92","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR29","first-page":"S429","volume":"25","author":"PI Aguayo-Hiraldo","year":"2019","unstructured":"Aguayo-Hiraldo PI et al (2019) Outcomes of umbilical cord transplant [UCBT] conditioned without serotherapy for pediatric malignant and non-malignant diseases: Texas Children's Hospital experience. Biol Blood Marrow Transplant 25:S429","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR30","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.bbmt.2018.12.083","volume":"25","author":"MH Albert","year":"2019","unstructured":"Albert MH et al (2019) Busulfan\/fludarabine- or treosulfan\/fludarabine-based conditioning regimen for patients with Wiskott-Aldrich syndrome\u2014an EBMT inborn errors working party and Scetide study. Biol Blood Marrow Transplant 25:S16","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR31","unstructured":"https:\/\/tct.confex.com\/tct\/2019\/meetingapp.cgi\/Paper\/13801\n                    \n                  . Accessed 3 May 2019"},{"key":"1152_CR32","unstructured":"https:\/\/tct.confex.com\/tct\/2019\/meetingapp.cgi\/Paper\/13761\n                    \n                  . Accessed 3 May 2019"},{"key":"1152_CR33","unstructured":"https:\/\/tct.confex.com\/tct\/2019\/meetingapp.cgi\/Paper\/13690\n                    \n                  . Accessed 3 May 2019"},{"key":"1152_CR34","doi-asserted-by":"publisher","first-page":"S435","DOI":"10.1016\/j.bbmt.2018.12.504","volume":"25","author":"A Oko-Odoi","year":"2019","unstructured":"Oko-Odoi A (2019) Managing the psychosocial complexities of sickle cell disease with multiple comorbidities during allogeneic hematopoietic stem cell transplantation with supportive nursing care. Biol Blood Marrow Transplant 25:S435","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR35","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1016\/j.bbmt.2018.12.493","volume":"25","author":"C Vogel","year":"2019","unstructured":"Vogel C et al (2019) End-of-life aspects in a hematopoietic stem cell transplantation unit: the integration of palliative care group in the transplant process. Biol Blood Marrow Transplant 25:S430","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR36","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.bbmt.2018.12.421","volume":"25","author":"RJ Lin","year":"2019","unstructured":"Lin RJ et al (2019) Characteristics of peri-transplant palliative supportive care consultation among older allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 25:S134","journal-title":"Biol Blood Marrow Transplant"},{"key":"1152_CR37","doi-asserted-by":"publisher","first-page":"S271","DOI":"10.1016\/j.bbmt.2018.12.202","volume":"25","author":"CS Ferraro","year":"2019","unstructured":"Ferraro CS et al (2019) Patient reported review of symptoms in survivorship clinic. Biol Blood Marrow Transplant 25:S271","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1152_CR38","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.1016\/j.bbmt.2018.12.612","volume":"25","author":"RB Salit","year":"2019","unstructured":"Salit RB, Lee SJ, Burns LJ, Shaw BE, Nakano C, Majhail NS, Bhatt NS, Wood WA, Syrjala KL (2019) Guidelines and support for return to work after hematopoietic cell transplantation. Biol Blood Marrow Transplant 25(3):S376\u2013S377","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-019-01152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-019-01152-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-019-01152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T23:21:49Z","timestamp":1592608909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-019-01152-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1007\/s12288-019-01152-3","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The article complies with the ethical standards by declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standard"}}]}}